Please assess the completion status of the following clinical trial:

Trial Title: A CFit Study - Baseline

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
GROUP 1:~Cystic fibrosis (CF) with established CF-related diabetes:~Inclusion Criteria:~* Males and females ≥ 12 years of age~* CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride \> 60 mmol·L-1 \> 100 mg sweat) and, where possible, diagnostic genotyping~* Established CFRD in accordance with the most recent American Diabetes Association positional statement. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:~  * 2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)~ * Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)~ * Glycated hemoglobin ≥ 48 mmol/mol~* No contraindications to performing exhaustive exercise~* Can understand and cooperate with the study protocol~* No increase in symptoms or weight loss in the preceding 2 weeks~Exclusion Criteria:~* Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders (arthritis, joint or muscle disease) and cardiovascular disease (congenital heart disease or cardiomyopathy).~* Unstable co-morbid asthma (daily pulmonary function variability of \>20%)~* Is pregnant during the initial screening process~* Unable to understand or cooperate with the study protocol due to learning difficulties or otherwise~* Not of a suitable age for testing~GROUP 2:~Cystic fibrosis (CF) without established CF-related diabetes:~Inclusion Criteria:~* Males and females ≥ 12 years of age~* CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride \> 60 mmol·L-1 \> 100 mg sweat), where possible, diagnostic genotyping would also be desired~* No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above).~* No contraindications to performing exhaustive exercise~* Can understand and cooperate with the study protocol~* No increase in symptoms or weight loss in the preceding 2 weeks~Exclusion Criteria:~* Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders (arthritis, joint or muscle disease) and cardiovascular disease (congenital heart disease or cardiomyopathy).~* Unstable co-morbid asthma (daily pulmonary function variability of \>20%)~* Is pregnant during the initial screening process~* Unable to understand or cooperate with the study protocol due to learning difficulties or otherwise~* Not of a suitable age for testing~* Not a suitable age- and gender-match for those with CFRD~Exclusion during testing:~* Onset of acute infection~* Becomes and/or is tested to be pregnant following enrolment to the study~* Unable to understand or cooperate with study protocol~* The individual does not wish to participate further~GROUP 3:~Healthy age- and gender-matched control participants:~Inclusion Criteria:~* Age- and gender~Exclusion Criteria:~* Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders (arthritis, joint or muscle disease), respiratory and cardiovascular disease (congenital heart disease or cardiomyopathy).~* Is pregnant during the initial screening process~* Unable to understand or cooperate with the study protocol due to learning difficulties or otherwise~* Not a suitable age- and gender-match for those with CFRD~Exclusion during testing:~* Onset of acute illness or injury~* Becomes and/or is tested to be pregnant following enrolment to the study~* Unable to understand or cooperate with study protocol~* The individual does not wish to participate further

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cystic fibrosis (CF) with established CF-related diabetes (Type: None): Cystic fibrosis (CF) with established CF-related diabetes~Inclusion criteria:~* Males and females ≥ 12 years of age~* CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride \> 60 mmol·L-1 \> 100 mg sweat) and, where possible, diagnostic genotyping~* Established CFRD in accordance with the most recent American Diabetes Association positional statement\]. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:~  * 2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)~ * Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)~ * Glycated hemoglobin ≥ 48 mmol/mol~* No contraindications to performing exhaustive exercise~* Can understand and cooperate with the study protocol~* No increase in symptoms or weight loss in the preceding 2 weeks
- Cystic fibrosis (CF) without established CF-related diabetes (Type: None): Cystic fibrosis (CF) without established CF-related diabetes~Inclusion criteria:~* Males and females ≥ 12 years of age~* CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride \> 60 mmol·L-1 \> 100 mg sweat), where possible, diagnostic genotyping would also be desired~* No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above; \[110\]).~* No contraindications to performing exhaustive exercise~* Can understand and cooperate with the study protocol~* No increase in symptoms or weight loss in the preceding 2 weeks
- Healthy controls (Type: None): Age- and gender-matched healthy control participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues